HRAS Q61R
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene HRAS
Variant Q61R
Impact List missense
Protein Effect loss of function
Gene Variant Descriptions HRAS Q61R does not lie within any known functional domains of the Hras protein (UniProt.org). Q61R confers a loss of function to Hras protein as indicated by decreased Hras GTPase activity in an in vitro assay and transformation of cells in culture (PMID: 3510078).
Associated Drug Resistance
Category Variants Paths

HRAS mutant HRAS act mut HRAS Q61R

HRAS mutant HRAS Q61X HRAS Q61R

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_005343.4
gDNA chr11:g.533874T>C
cDNA c.182A>G
Protein p.Q61R
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_005343.3 chr11:g.533874T>C c.182A>G p.Q61R RefSeq GRCh38/hg38
NM_001130442 chr11:g.533874T>C c.182A>G p.Q61R RefSeq GRCh38/hg38
NM_001130442.2 chr11:g.533874T>C c.182A>G p.Q61R RefSeq GRCh38/hg38
NM_005343 chr11:g.533874T>C c.182A>G p.Q61R RefSeq GRCh38/hg38
NM_001130442.3 chr11:g.533874T>C c.182A>G p.Q61R RefSeq GRCh38/hg38
NM_176795 chr11:g.533874T>C c.182A>G p.Q61R RefSeq GRCh38/hg38
NM_176795.5 chr11:g.533874T>C c.182A>G p.Q61R RefSeq GRCh38/hg38
NM_005343.4 chr11:g.533874T>C c.182A>G p.Q61R RefSeq GRCh38/hg38
NM_176795.4 chr11:g.533874T>C c.182A>G p.Q61R RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
HRAS Q61R Advanced Solid Tumor sensitive Everolimus Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Afinitor (everolimus) in culture (PMID: 26544513). 26544513
HRAS Q61R Advanced Solid Tumor sensitive Binimetinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing HRAS Q61R demonstrated sensitivity to growth inhibition by Mektovi (binimetinib) in culture (PMID: 26544513). 26544513
HRAS Q61R bladder urothelial carcinoma predicted - sensitive Tipifarnib Case Reports/Case Series Actionable In a Phase II trial, Zarnestra (tipifarnib) demonstrated manageable toxicity profile, resulted in an objective response rate of 33.3% (5/15) in patients with transitional cell carcinoma harboring HRAS mutations, 2 patients with bladder urothelial carcinoma harbored HRAS Q61R achieved partial responses (PMID: 32636318; NCT02535650). 32636318